NCT06677138View on ClinicalTrials.gov

PK Study of Gefurulimab SC in Healthy Chinese Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

March 19, 2025

Study Completion Date

March 19, 2025

Conditions
Healthy
Interventions
DRUG

gefurulimab

Participants will receive gefurulimab subcutaneously (SC).

Trial Locations (1)

201107

Research Site, Shanghai

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY